.jpg)
In this episode of the Oncology Brothers, we delved into the latest advancements in the treatment of extensive stage small cell lung cancer, specifically focusing on the IMforte data and its clinical implications. We are joined by esteemed thoracic medical oncologists Drs. Isabel Preeshagul, Ticiana Leal, and Stephen Liu, who provided valuable insights into the recent findings presented at ASCO 2025 and World Lung 2025. We discussed the IMforte study, which evaluates the use of lurbinectedin in combination with atezolizumab as a maintenance therapy following induction treatment with carboplatin and etoposide. The results show a significant improvement in overall survival, with a hazard ratio of 0.73, and a doubling of progression-free survival (PFS) from 2.1 months with atezolizumab alone to 5.4 months with the addition of lurbinectedin.
Our guests emphasized the importance of proactive management of side effects, particularly hematologic toxicities, and the role of prophylactic growth factors in maintaining patient safety during treatment. We also touched on patient selection criteria for this new standard of care and the significance of shared decision-making in treatment planning.
As we wrapped up, we highlighted the critical need for early intervention in small cell lung cancer to improve patient outcomes, as many patients do not receive second-line therapies after progression. This episode underscored the exciting developments in oncology that are providing hope for patients facing this challenging disease.